he maker of the popular painkiller Nurofen was ordered on Monday to remove some of its brands from store shelves in Australia.
The Federal Court ruled that UK-based drug giant Reckitt Benckiser made misleading claims about the pills’ effectiveness.
The court said Nurofen’s back pain, period pain, migraine pain, and tension headache brands were identical to standard Nurofen – despite being nearly double the price.
Ruling on complaints made by the fair trading regulator, the Australian Competition and Consumer Commission, the court found all the products contained the same amount of the active ingredient: 342 milligrams of ibuprofen lysine.
The drugs were “no more effective at treating the type of pain described on its packaging than any of the other Nurofen Specific Pain products”, the court ruled, according to an ACCC statement.
Full content: Market Watch
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI